Shermaine Tilley

Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada.

The Public Health Research Institute Center provides biomedical research. The private company is based in Newark, NJ.

DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada.

Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada.

CTI Life Sciences Fund LP invests in high quality emerging life sciences companies located in Canada. The fund targets companies operating in the fields of pharmaceuticals and biotechnology companies. It provides financing for seed, early and development stage capital requirements. It also act as lead investor.

CFA Society Toronto supports the professional and business development of charterholders. It provides member services including educational programs, sponsored events, employment postings, and networking opportunities. The company was founded in 1936 and is headquartered in Toronto, Canada.

NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON.